Promising combo targets tough esophageal cancer
NCT ID NCT04229459
First seen Jan 19, 2026 · Last updated May 12, 2026 · Updated 18 times
Summary
This study tested whether adding two immunotherapy drugs, nivolumab and cetuximab, to standard chemoradiation could improve outcomes for people with a certain type of advanced esophageal cancer. Twelve participants who had not received prior treatment received the drug combination before surgery. The main goal was to see if the cancer completely disappeared after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rabin Medical Center
Petah Tikva, Israel
Conditions
Explore the condition pages connected to this study.